BRCA
  • About Us
    • Leadership
    • Scientific Advisory Committee
    • Impact Reports
    • Press Releases
  • Grants
    • Research Program
    • Previously Funded Grants
    • Key Research References
  • Resources
    • FAQ: Living with BRCA
    • TARGET: A Genetic Education Webtool
    • Knowledge Center
    • Clinical Trials
  • News
  • Contact

2023 Grant Recipients

Posted OnJune 30, 2023 byPriscilla Kennedy

BRCA Research & Cure Alliance Grant Announcement – June 30, 2023

Funded research includes grants to U.S. and international academic institutions: projects include research, screening, treatment, and outreach efforts for men with BRCA genetic mutations.

 

On June 30, 2023, the BRCA Research & Cure Alliance (CureBRCA) announced plans to fund $2.3 Million for five important research endeavors. The BRCA Research & Cure Alliance believes that the knowledge uncovered by this research could be the key to understanding prostate cancer risk, prevention and interception, and bringing hope to the multitude of people who carry BRCA mutations and are at risk for prostate cancer. Collectively, the BRCA-related prostate cancer research projects include: large global collaborative studies addressing prevention, multi-institutional screening efforts, and outreach to identify and provide more resources for male carriers of prostate cancer risk associated genetic BRCA 1/2 variants.


2023 CureBRCA Research Grants

 

Rosalind Eeles, PhD; The Institute of Cancer Research. U.K.

“BRCA1 And BRCA2 Mutation Carriers – Prostate Cancer Screening And Treatment Outcomes”

 

Ephrat Levy-Lahad, MD; Shaare Zedek Medical Center, Israel

“Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Male BRCA carriers with Prostate Cancer”

 

Daniel W. Lin, MD; University of Washington

“Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease (PATROL)”

 

Katherine Nathanson, MD; University of Pennsylvania

“Expanding The Spectrum of BRCA1/2 Pathogenic Variants”

 

Kenneth Offit, MD, MPH; Memorial Sloan Kettering Cancer Center

“Targeting BRCA1/2 Modifiers of Risk for Prostate Cancer”

Previous PostHelicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer
Next PostFDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer
  • Facebook Twitter Bluesky Linkedin Instagram
    • About Us
    • Press
    • Resources
    • News
    • Privacy Policy
  • Contact
  • © 2025 CureBRCA